We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Indian generic drug manufacturer Dr. Reddy’s Laboratories has signed a deal to acquire Germany’s Betapharm Arzeniemittel GmbH for roughly $570 million.
TyRx Pharma has signed an exclusive license agreement with Baylor College of Medicine and The University of Texas M. D. Anderson Cancer Center for the use of the institutions’ patents and associated technologies to develop cardiovascular and surgical medical devices.
Boston Scientific’s planned acquisition of Guidant foretells limits on the current strategy of incubating new technologies as start-ups and then selling them to large, established companies due to further industry consolidation, a venture capital firm says.
On the heels of receiving an FDA warning letter, Boston Scientific’s stock continues to fall and the Guidant deal may not be as solid as it was believed to be.
The FDA put Boston Scientific on notice last week that the company’s quality management practices are insufficient, with “serious regulatory problems” found at numerous facilities and that the agency stood ready to take action without further notice.
Boston Scientific is keeping Guidant champing at the bit, raising its offer to purchase the device manufacturer to $80 per share in the contest between Boston Scientific and Johnson & Johnson (J&J) to acquire the company.
Medical journal editors are cracking down on authors who fail to disclose ties to drug or device companies, following several disclosures that peer-reviewed articles were written by freelance writers hired by drug companies.